MBX Biosciences Inc. Common Stock (MBX)

About MBX

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

63

Website

mbxbio.com/

Fundamentals

1-day range

$62.99$66.14

Market cap

$3.19B

P/E (trailing)

—

P/E (forward)

-15.93

EPS (trailing)

$-2.41

Dividend yield

—

Beta

1.46

Avg. volume

759.9K

Forecasts

11 analyst ratings

MBX Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MBX

  MBX Biosciences Inc. Common Stock

  $63.04

  ▼ 5.05%
  Market cap $3.19BP/E —
  $9.63$72.64
• NAMS

  NewAmsterdam Pharma Company N.V. Ordinary Shares

  $25.9

  ▼ 3.32%
  Market cap $3.23BP/E —
  $23.05$42.21
• ARQT

  Arcutis Biotherapeutics Inc. Common Stock

  $23.78

  ▼ 4.38%
  Market cap $3.31BP/E 113.86
  $15.1$31.77
• IRON

  Disc Medicine Inc. Common Stock

  $80.01

  ▼ 3.08%
  Market cap $2.97BP/E —
  $40$99.5
• IMNM

  Immunome Inc. Common Stock

  $27.57

  ▼ 4.50%
  Market cap $2.92BP/E —
  $8.67$30.06
• ALMS

  Alumis Inc. Common Stock

  $22.38

  ▼ 3.58%
  Market cap $3.54BP/E —
  $3.76$31.35
• TLX

  Telix Pharmaceuticals Limited American Depositary Shares

  $11.28

  ▼ 0.84%
  Market cap $3.60BP/E —
  $6.28$12.5

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
  SeekingAlpha · 8/28/2026
• MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism
  benzinga · 8/27/2026
• MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism
  Benzinga · 8/27/2026
• JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target
  Benzinga · 8/21/2026
• UMH Properties and 4 More Stocks See Action From Activist Investors
  Yahoo · 8/14/2026
• Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88
  Benzinga · 8/10/2026
• MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
  Yahoo · 8/6/2026
• MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate
  Benzinga · 8/6/2026
• Stock Market Checklist Helps Uncover Winners In Hot Biotechs
  Yahoo · 7/31/2026

• Azoulay Salomon · August 4, 2026 · Sale

  370 @ $65.77
• John W. Smither · August 3, 2026 · Grant

  130.0K
• John W. Smither · August 3, 2026 · Grant

  28.0K
• Hoerter Steven L. · August 3, 2026 · Grant

  331.0K
• Hoerter Steven L. · August 3, 2026 · Grant

  71.0K
• Ryder Steven · June 4, 2026 · Grant

  12.5K
• Aynechi Tiba · June 4, 2026 · Grant

  12.5K
• Stelzer Laurie · June 4, 2026 · Grant

  12.5K
• Hoerter Steven L. · June 4, 2026 · Grant

  12.5K
• Pescovitz Ora H. · June 4, 2026 · Grant

  12.5K
• Patrick J. Heron · June 4, 2026 · Grant

  12.5K
• Edward T. Mathers · June 4, 2026 · Grant

  12.5K
• Azoulay Salomon · May 8, 2026 · Option Exercise

  15.0K @ $16
• Azoulay Salomon · May 8, 2026 · Option Exercise

  55.0K @ $10.46
• Azoulay Salomon · May 8, 2026 · Sale

  15.0K @ $38.3

Institutional Ownership

March 31, 2026

Total shares held

52.03M

Total value held

$1.52B

Institutional holders

151